Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INS-DRiP neoantigen-specific regulatory T cells
- Development stage
- Preclinical
- Lead developer
- Leiden University Medical Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
INS-DRiP neoantigen-specific regulatory T cells are an investigational autologous cell therapy consisting of regulatory T cells (Tregs) induced against the islet neoantigen INS-DRiP (insulin defective ribosomal product). Developed by researchers at the Leiden University Medical Center (LUMC), these Tregs are generated in vitro by co-culturing naïve CD4+ T cells with autologous tolerogenic dendritic cells (tolDCs) pulsed with the INS-DRiP neoantigen. INS-DRiP is an immunogenic polypeptide produced by translational misreading of insulin mRNA in pancreatic beta cells under endoplasmic reticulum (ER) stress. By targeting this neoantigen, the induced Tregs are designed to suppress the autoimmune destruction of beta cells, offering a potential therapeutic approach for the prevention and treatment of type 1 diabetes (T1D).
- Other names
- INS-DRiP-specific iTregsINS-DRiP-specific regulatory T cellsINS-DRiP-specific Tregs
02
Targets
HLA-DR (Human leukocyte antigen DR)
Beyond the preview
Go deeper on INS-DRiP neoantigen-specific regulatory T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INS-DRiP neoantigen-specific regulatory T cells.